Xian-Janssen Receives SFDA's Approval For Velcade
This article was originally published in PharmAsia News
Executive Summary
Xian-Janssen has obtained approval from China's State FDA for Velcade (bortezomib) for treatment of mantle cell lymphoma, representing China's first drug for the disease. MCL, originating in the lymph nodes, is a lymphoma subtype with poor prognosis and short survival time. In China, its incidence rate ranks 9 and 10 respectively in all male and female malignant tumors. Bortezomib appeared as the world's first targeted protease inhibitor and received approval from U.S. FDA in 2008 for first- and second-line treatment for multiple myeloma and MCL, respectively. According to Phase II clinical trials jointly conducted by 35 clinical centers in the U.S., U.K. and Germany, bortezomib single-agent has shown effectiveness in the treatment of relapsed or refractory MCL. (Click here for more - Chinese language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.